**Open Access Full Text Article** 

## RETRACTION

# TRIM31 Promotes Glioma Proliferation and Invasion Through Activating NF-κB Pathway [Retraction]

Zhou L, Deng ZZ, Li HY, et al. Onco Targets Ther. 2019;12:2289-2297.

We, the Editor and Publisher of the journal OncoTargets and Therapy have retracted the published article.

Following publication of the article, concerns were raised about the duplication of images from Figures 2 and 3 with images from an unrelated article. Specifically,

• The image for Figure 2D, U87MG, Vector, and Figure 3D, LN-229, Vector has been duplicated with the image for Figure 3D, ZR-75-1, NC, and Figure 2D, MCF-7, Vector, respectively, from Peng L, Deng X, Gan X, et al. Targeting of TLE3 by miR-3677 in human breast cancer promotes cell proliferation, migration and invasion. *Oncology Letters*. 2020;19:1409-1417. <u>https://doi.org/10.3892/ol.2019.11241</u>.

The corresponding author was cooperative and did respond to our queries but was unable to provide a satisfactory explanation for how the images came to be duplicated or provide satisfactory original data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the Publisher and Editor requested to retract the article and the corresponding author was notified of this decision.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

#### OncoTargets and Therapy

### Dovepress

67 I

#### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S491281

Received: 13 August 2024 Accepted: 13 August 2024 Published: 20 August 2024

#### OncoTargets and Therapy 2024:17 671

© 2024 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution — Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission for Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).